New liver tests aim to better predict outcomes in End-Stage disease
NCT ID NCT01907074
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a new type of liver function test using a substance called cholate could better assess the severity of liver disease in people with end-stage liver disease. The goal was to improve how doctors predict outcomes and guide treatment. The study included 103 participants, including patients with severe liver disease and living liver donors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells predict herpesvirus danger in transplant patients?
- Muscle quality on MRI may foretell liver transplant success
- Better crystal ball for liver crisis: new scores put to the test
- A machine that keeps donor livers alive outside the body — could it transform transplantation?
- Frailty test could predict who survives liver transplant waiting list
- Could a single infusion of 'Trainer' cells free liver transplant patients from lifelong drugs?